Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?

Purpose This multicenter retrospective study assessed the real-world effectiveness and safety of upadacitinib in adults with moderate-to-severe atopic dermatitis across eight centers in central Italy.Materials and methods A total of 150 patients received upadacitinib 15 mg or 30 mg daily as monother...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Edoardo Mortato, Niccolò Gori, Giacomo Caldarola, Marina Talamonti, Claudia Paganini, Luisa Boeti, Filomena Russo, Teresa Grieco, Ersilia Tolino, Gaia Moretta, Flavia Pigliacelli, Rosa Coppola, Domenico Giordano, Camilla Chello, Concetta Potenza, Maria Concetta Fargnoli, Vincenzo Panasiti, Barbara Cocuroccia, Ketty Peris, Marco Galluzzo
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Taylor & Francis Group 2025-12-01
Цуврал:	Journal of Dermatological Treatment
Нөхцлүүд:	Upadacitinib atopic dermatitis head and neck dermatitis JAK inhibitors
Онлайн хандалт:	https://www.tandfonline.com/doi/10.1080/09546634.2025.2509541
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!